Catecholaminergic and serotonergic enhancer site (CAE/SAE site)

The Catecholaminergic and Serotonergic Enhancer (CAE/SAE) site is a specialized pharmacological target that modulates the release of monoamine neurotransmitters in a state-dependent manner. Unlike traditional psychostimulants like amphetamine, which trigger non-physiological neurotransmitter release, or reuptake inhibitors like cocaine, substances targeting the CAE/SAE site enhance the amount of dopamine, norepinephrine, and serotonin released specifically in response to action potentials (Knoll, J., 1998) [1]. This enhancer effect is thought to strengthen physiological signaling without depleting neurotransmitter vesicles or causing the typical side effects of over-stimulation (Shimazu, S., et al., 2003) [3]. The prototype molecule for this site is (-)-BPAP, which has shown potent activity in preclinical models of depression and neurodegeneration (Knoll, J., et al., 1999) [2]. Research indicates that this site may be molecularly linked to the Sigma-1 receptor, which acts as a molecular chaperone to modulate various ion channels and neurotransmitter receptors (Miklya, I., 2016) [4]. Therapeutic applications focus on Parkinson's disease, Alzheimer's disease, and treatment-resistant depression, aiming to restore monoaminergic tone and provide neuroprotection (Knoll, J., 2001) [5].

Other names

Enhancer-sensitive siteCAE/SAE enhancer siteTrophic-factor-like enhancer siteEnhancer-sensitive receptor

Enhancement of impulse-propagation-mediated release of catecholamines and serotonin